{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T14:45:01Z","timestamp":1746715501221,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1038\/s41409-024-02301-7","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T08:01:56Z","timestamp":1715241716000},"page":"1181-1183","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy"],"prefix":"10.1038","volume":"59","author":[{"given":"George S.","family":"Mellgard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divaya","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus Y.","family":"Mapara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jai","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-3003","authenticated-orcid":false,"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"2301_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385:46\u201358.","journal-title":"N Engl J Med"},{"key":"2301_CR2","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","volume":"33","author":"A D\u2019Souza","year":"2015","unstructured":"D\u2019Souza A, Dispenzieri A, Wirk B, Zhang M, Huang J, Gertz MA, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015;33:3741.","journal-title":"J Clin Oncol."},{"key":"2301_CR3","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1182\/blood-2021-152540","volume":"138","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Minnema MC, Dimopoulos M, Merlini G, Theodorakakou F, Fotiou D, et al. Efficacy and safety of daratumumab monotherapy in newly diagnosed patients with stage 3B light chain amyloidosis: a phase 2 study by the European Myeloma Network. Blood. 2021;138:2730.","journal-title":"Blood"},{"key":"2301_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood.2019004460","volume":"136","author":"G Palladini","year":"2020","unstructured":"Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136:71\u201380.","journal-title":"Blood"},{"key":"2301_CR5","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1200\/JCO.19.01721","volume":"38","author":"S Lentzsch","year":"2020","unstructured":"Lentzsch S, Lagos GG, Comenzo RL, Zonder JA, Osman K, Pan S, et al. Bendamustine with dexamethasone in relapsed\/refractory systemic light-chain amyloidosis: results of a phase II study. J Clin Oncol 2020;38:1455.","journal-title":"J Clin Oncol"},{"key":"2301_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","volume":"130","author":"V Sanchorawala","year":"2017","unstructured":"Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, et al. A phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130:597\u2013605.","journal-title":"Blood"},{"key":"2301_CR7","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1182\/blood-2016-04-710822","volume":"128","author":"V Sanchorawala","year":"2016","unstructured":"Sanchorawala V, Shelton AC, Lo S, Varga C, Sloan JM, Seldin DC. Pomalidomide and dexamethasone Win the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood. 2016;128:1059\u201362.","journal-title":"Blood"},{"key":"2301_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00950-3","volume":"13","author":"R Chakraborty","year":"2023","unstructured":"Chakraborty R, Bhutani D, Maurer MS, Mohan M, Lentzsch S, D\u2019souza A. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer J. 2023;13:172.","journal-title":"Blood Cancer J"},{"key":"2301_CR9","doi-asserted-by":"crossref","unstructured":"Forgeard N, Elessa D, Carpinteiro A, Belhadj K, Minnema M, Roussel M, et al. Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series. Blood J. 2024;143:734\u20137.","DOI":"10.1182\/blood.2023022937"},{"key":"2301_CR10","doi-asserted-by":"crossref","unstructured":"Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, et al. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2024;109:906\u201314.","DOI":"10.3324\/haematol.2023.283590"},{"key":"2301_CR11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/ajh.26641","volume":"97","author":"JN Gustine","year":"2022","unstructured":"Gustine JN, Staron A, Szalat RE, Mendelson LM, Joshi T, Ruberg FL, et al. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25\u2010year longitudinal study. Am J Hematol. 2022;97:1189\u201399.","journal-title":"Am J Hematol"},{"key":"2301_CR12","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1182\/blood-2023-190813","volume":"142","author":"A Staron","year":"2023","unstructured":"Staron A, Burks EJ, Szalat RE, Sanchorawala V. Prospective Evaluation of Measurable Residual Disease (MRD) and Sustainability of the Response in Patients with Systemic AL Amyloidosis Treated with Daratumumab. Blood. 2023;142:3405.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02301-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02301-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02301-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T09:16:22Z","timestamp":1722590182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02301-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2301"],"URL":"https:\/\/doi.org\/10.1038\/s41409-024-02301-7","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"assertion":[{"value":"12 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}